Research progress of non-insulin hypoglycemic drugs in the treatment of type 1 diabetes mellitus
- VernacularTitle:非胰岛素类降糖药物在1型糖尿病治疗中的研究进展
- Author:
Zejie XU
1
;
Jiaoni ZHENG
1
;
Jing LUO
1
;
Liangyu WANG
1
;
Wei YAN
2
;
Qiang HE
1
;
Xuefeng SHAN
1
Author Information
1. Dept. of Pharmacy，Bishan Hospital of Chongqing Medical University/Bishan Hospital of Chongqing，Chongqing 402760，China
2. School of Pharmacy，Chongqing Medical University，Chongqing 400042，China
- Publication Type:Journal Article
- Keywords:
non-insulin hypoglycemic drugs;
type 1 diabetes mellitus;
pramlintide;
metformin;
sodium-glucose co-transporter
- From:
China Pharmacy
2026;37(2):263-267
- CountryChina
- Language:Chinese
-
Abstract:
Traditional treatment for type 1 diabetes mellitus （T1DM） primarily involves insulin replacement， yet some patients encounter issues such as significant blood glucose fluctuations， high risk of hypoglycemia， and weight gain. In recent years， the adjuvant therapeutic role of non-insulin hypoglycemic drugs in T1DM has gradually gained attention. This article reviews the mechanisms of action and clinical research progress of five types of non-insulin hypoglycemic drugs in the treatment of T1DM： amylin analogues （pramlintide）， biguanides （metformin）， sodium-glucose co-transporter 2 inhibitor， dipeptidyl peptidase-4 inhibitor， and glucagon-like peptide-1 receptor agonist. It is found that these drugs can enhance clinical benefits for T1DM patients by improving insulin sensitivity， delaying gastric emptying， promoting urinary glucose excretion， and regulating incretin levels， thereby reducing glycated hemoglobin levels， decreasing insulin dosage， and managing body weight. Simultaneously， these drugs also present limitations such as low patient compliance due to complex dosing regimens， increased risk of diabetic ketoacidosis， and heterogeneity in glycemic control. Future research could focus on developing individualized treatment strategies， combining pharmacogenomics with novel biomarkers to precisely identify subpopulations of patients who may benefit， and delving into the potential value of these drugs in delaying diabetic vascular complications and improving patients’ quality of life.
